Loading...

Calliditas Therapeutics AB (publ)

CLTEF•PNK
Healthcare
Biotechnology
$3.75
$0.25(7.14%)

Calliditas Therapeutics AB (publ) (CLTEF) Stock Overview

Explore Calliditas Therapeutics AB (publ)’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.9/100

Key Financials

Market Cap250.7M
P/E Ratio-48.26
EPS (TTM)$-1.07
ROE-0.43%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$4.32

CLTEF Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Calliditas Therapeutics AB (publ) (CLTEF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 42.91, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $4.32.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -48.26 and a market capitalization of 250.7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
N/A
6-Month Change
N/A
Year-to-Date (YTD) Change
N/A
1-Year Change
N/A
3-Year Change
N/A
5-Year Change
N/A
All-Time (Max) Change
N/A

Contact Information

https://www.calliditas.se
46 84 11 30 05
Kungsbron 1, D5, Stockholm, 111 22

Company Facts

178 Employees
IPO DateSep 16, 2020
CountrySE
Actively Trading

Frequently Asked Questions

;